Vaximm

Vaximm is pioneering an innovative oral immunotherapy platform that activates cytotoxic T-cells to fight solid tumors, differentiating itself through its non-invasive administration route. The company has built a pipeline targeting clinically-validated tumor-associated antigens, with its lead program in glioblastoma having reached Phase 1/2 clinical testing. Founded by renowned immunologists and headquartered in Basel, Switzerland, Vaximm operates as a private, preclinical to early clinical-stage biotech seeking to address significant unmet needs in oncology. Its strategy hinges on demonstrating proof-of-concept for oral T-cell vaccines to attract partnership and further investment.

Oral, live-attenuated bacterial vector platform designed to deliver tumor-associated antigens to the gut immune system, activating a systemic, tumor-targeted cytotoxic CD8+ T-cell response.

Vaximm competes in the broad and competitive field of cancer immunotherapy, facing rivals developing injectable cancer vaccines, cell therapies, and checkpoint inhibitors. Its primary differentiation is its oral delivery route, which positions it against other oral immunomodulators and niche vaccine approaches. Key competitors include large pharma with extensive I-O portfolios and other biotechs focused on T-cell engagement platforms.